Lessons Learned, Foundation Laid - Time For The Clinical Leap

Abstract

Cardiovascular tissue engineering has made significant strides since the 1970s, when initial efforts sought to reduce the thrombogenicity of total artificial hearts using cultured endothelial layers. Over the decades, however, the field has experienced repeated cycles of rediscovery and setbacks. Unlike other disruptive medical innovations, its greatest challenge remains the failure to achieve broad clinical translation.

While research enthusiasm has spread globally and engaged diverse scientific communities, it is time for the clinician-scientist to reassert a central role - bridging mechanistic insights with therapeutic application. This is essential for two reasons. First, to restore an understanding of the distinct healing-biology of cardiovascular prostheses in humans. Animal models have often misrepresented human healing responses, leading to incorrect assumptions and divergent, non-translatable research paths. Second, clinical needs have changed. Whereas early efforts were driven by the need for coronary bypass grafts, priorities have shifted to transcatheter valve therapies, where durable soft-leaflet solutions are urgently needed.

Despite past setbacks, a coherent framework has emerged that can guide global efforts. Central to this is renewed recognition of human-specific healing impediments: complete transanastomotic endothelialization does not occur in humans, and compacting fibrinogen-rich thrombus formation inhibits transmural tissue ingrowth.

Against this backdrop stand key insights from decades of research:

1. Autologous in vitro endothelialization markedly improves prosthetic performance in patients.
2. Transmural tissue ingrowth is vital for in-situ endothelialization.
3. Such sprouting must precede hostile fibrin accumulation that would otherwise prevent integration.
4. Healing must conclude before scaffold degradation induces fibrosis that blocks further ingrowth.

All core elements are now in place, backed by extensive clinical proof-of-principle. The path forward requires the reintegration of the clinician-scientist to lead this promising field toward successful therapeutic translation.